Lantern Pharma Inc — Quarterly Financial Statistics (NASDAQ:LTRN) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -5.58 M-3.97 M-4.38 M-3.94 M-4.57 M -16.86 M Cash from investing activities 680.34 K3.45 M3.24 M3.59 M5.93 M 16.21 M Cash from financing activities 11.99 K000971.78 K 971.78 K Free cash flow -5.59 M-3.97 M-4.38 M-3.94 M-4.57 M -16.86 M

Nouvelles

La FDA accorde la désignation de médicament orphelin au LP-284 de Lantern Pharma pour les sarcomes

FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas

Le médicament anticancéreux LP-184 de Lantern montre des résultats prometteurs en essai de phase 1a

Lantern’s cancer drug LP-184 shows promise in phase 1a trial

Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Lantern Pharma Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2025-11-15

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Disney, Brookfield, Nu Holdings and more set to report earnings Thursday

Les actionnaires de Lantern Pharma élisent des administrateurs et approuvent la révision des options d’achat d’actions

Lantern Pharma shareholders elect directors and approve stock option repricing

Le titre de Lantern Pharma grimpe après que le médicament anticancéreux LP-184 atteint ses objectifs d’essai

Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints